Pimecrolimus API

Name	Pimecrolimus
Chinese name	吡美莫司
Cas Number	137071-32-0
Source
Qualifications	USDMF/-/-/-/-

Pimecrolimus is a new generation of immunosuppressive drugs developed by Novartis of Switzerland and first launched in the UK in 2002. Pimecrolimus is a macrolide anti-inflammatory drug. The main mechanism is to use the ascomycin macrolide in pimecrolimus to bind to specific receptors, inhibit T cells from producing interferon-γ and interleukins, and avoid inflammatory factors At the same time, it inhibits the production of leukotrienes, tumor necrosis factor-ɑ, histamine, etc. by mast cells and basophils, and pimecrolimus has inhibitory immune activity, anti-inflammatory and antipruritic effects. Compared with tacrolimus, clopetasol 17 valerate, etc., pimecrolimus has a higher affinity to the skin, and external use can penetrate the skin to further exert its effect; at the same time, pimecrolimus has higher selectivity, and external use It will not cause adverse reactions such as telangiectasia and atrophy of corticosteroids. Studies have pointed out that the combination of medium-wave high-energy ultraviolet rays and pimecrolimus has obvious curative effect in the treatment of vitiligo, with small adverse reactions, and is a safe and effective treatment method. In 2016, the global market for AD treatments for allergic dermatitis was approximately USD 3.3 billion, with a compound annual growth rate of 4% in the past 4 years.

Hot Tags: pimecrolimus api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Active Pharmaceutical Ingredient, Tippyridine Hydrochloride API, Dapoxetine API, Temozolomide API, Ranolazine API, Rasagiline Mesylate API

• Previous: Simethicone API
• Next: Melphalan API